Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka.

Chandima JeewandaraK A Chintha S JayampathiThushali RanasingheInoka Sepali AberathnaBanuri GunasekaraSaubhagya DanasekaraThashmi NimashaHeshan KuruppuOsanda DissanayakeNayanathara GamalathDinithi EkanayakeJewantha JayamaliGayasha SomathilakeDinuka GurugeRuwan WijayamuniAchala KamaladasaGraham S OggGathsaurie Neelika Malavige

Published in: PLOS global public health (2022)

The Sinopharm/ BBIBP-CorV vaccine appeared safe and induced high seroconversion rates and ACE2 blocking antibodies in pregnant mothers in the second and third trimester in pregnancy. However, the RBD binding antibodies and ACE2 blocking antibodies post-second dose were significantly higher in previously infected pregnant mothers post-second dose, suggesting that two doses of the vaccine are likely to be less immunogenic in previously unexposed individuals.

Keyphrases

pregnant women
preterm birth
angiotensin ii
angiotensin converting enzyme
pregnancy outcomes
high glucose
endothelial cells
gestational age
transcription factor
stress induced